Pure redox-sensitive paclitaxel-maleimide prodrug nanoparticles: Endogenous albumin-induced size switching and improved antitumor efficiency.
10.1016/j.apsb.2020.12.001
- Author:
Xinyu LOU
1
;
Dong ZHANG
2
;
Hao LING
2
;
Zhonggui HE
2
;
Jin SUN
2
;
Mengchi SUN
2
;
Dongchun LIU
1
Author Information
1. School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, China.
2. Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
- Publication Type:Journal Article
- Keywords:
Abraxane;
Breast cancer treatment;
Disulfide bond;
Maleimide;
Paclitaxel;
Prodrug-based nano-drug delivery systems;
Prodrug/albumin nanoaggregates;
Redox-sensitive
- From:
Acta Pharmaceutica Sinica B
2021;11(7):2048-2058
- CountryChina
- Language:English
-
Abstract:
A commercial albumin-bound paclitaxel nano-formulation has been considered a gold standard against breast cancer. However, its application still restricted unfavorable pharmacokinetics and the immunogenicity of exogenous albumin carrier. Herein, we report an albumin-bound tumor redox-responsive paclitaxel prodrugs nano-delivery strategy. Using diverse linkages (thioether bond and disulfide bond), paclitaxel (PTX) was conjugated with an albumin-binding maleimide (MAL) functional group. These pure PTX prodrugs could self-assemble to form uniform and spherical nanoparticles (NPs) in aqueous solution without any excipients. By immediately binding to blood circulating albumin after intravenous administration, NPs are rapidly disintegrated into small prodrug/albumin nanoaggregates
